De­sert­ed by Take­da, Mer­sana aban­dons lead drug

Mer­sana Ther­a­peu­tics’ rocky road in de­vel­op­ing its lead drug has cul­mi­nat­ed in the aban­don­ment of the ex­per­i­men­tal can­cer treat­ment, days af­ter its high-pro­file part­ner Take­da de­cid­ed to walk away from their deal.

Back in 2016, Take­da and its unit Mil­len­ni­um ex­pand­ed a pri­or part­ner­ship with Mer­sana by se­cur­ing the the ex-US com­mer­cial rights to the Cam­bridge, Mass­a­chu­setts-based com­pa­ny’s then-lead pre­clin­i­cal an­ti­body drug con­ju­gate — XMT-1522 — for $60 mil­lion up­front and a host of oth­er mile­stone pay­ments, which in tan­dem with their ex­ist­ing agree­ment added up to a $1 bil­lion-plus deal.

Take­da backed Mer­sana $MRSN on the promise of its next-gen an­ti­body-drug con­ju­gates (AD­Cs), or armed an­ti­bod­ies.

This po­tent class of drugs brings to­geth­er two in­gre­di­ents by chem­i­cal­ly link­ing an­ti­bod­ies to a bi­o­log­i­cal­ly ac­tive drug or cy­to­tox­ic com­pound. This com­bines the tar­get­ing ca­pa­bil­i­ties of an­ti­bod­ies — al­low­ing sen­si­tive dis­crim­i­na­tion be­tween healthy and can­cer tis­sues — with the cell-killing abil­i­ty of chemother­a­pies. While ex­ist­ing AD­Cs can be lim­it­ed to just a few ther­a­pies, Mer­sana’s tech plat­form is de­signed to pro­duce drugs that can link up with 12 to 15, in the­o­ry vast­ly en­hanc­ing the ther­a­peu­tic po­ten­tial of their crop of AD­Cs for dis­eases pre­vi­ous­ly out of reach.

An­na Pro­topa­pas

It was this ad­di­tion­al fire­pow­er that at­tract­ed Take­da to Mer­sana, which is run by for­mer Mil­len­ni­um chief An­na Pro­topa­pas. Mer­sana went pub­lic in 2017, but a year lat­er trou­ble was afoot. Last Ju­ly, Mer­sana re­port­ed a pa­tient death in a Phase I tri­al test­ing XMT-1522 in pa­tients with breast, gas­tric, and non-small cell lung can­cers whose tu­mors ex­press HER2. The com­pa­ny ac­knowl­edged the death could be re­lat­ed to the ex­per­i­men­tal drug, and the FDA slapped a par­tial clin­i­cal hold on the tri­al. Mer­sana’s oth­er can­cer drug-in-de­vel­op­ment, XMT-1536, was un­af­fect­ed.

By Sep­tem­ber, the com­pa­ny and the FDA agreed to a re­vamped de­vel­op­ment pro­gram for XMT-1522, and the agency lift­ed its hold. How­ev­er, it looks like Take­da man­age­ment de­cid­ed that the pro­gram, and in­deed Mer­sana’s tech, was too risky to con­tin­ue their col­lab­o­ra­tion. In an SEC fil­ing, Mer­sana said that the Japan­ese drug­mak­er’s Mil­len­ni­um unit had elect­ed to ter­mi­nate the part­ner­ship on Jan­u­ary 2.

In its press re­lease on Fri­day, Mer­sana said it had aban­doned the de­vel­op­ment of XMT-1522 al­to­geth­er to fo­cus on its oth­er ex­per­i­men­tal drug, XMT-1536. The com­pa­ny’s shares were down about 15% in ear­ly trad­ing.

“We have made the dif­fi­cult de­ci­sion to ter­mi­nate the fur­ther de­vel­op­ment of XMT-1522 de­spite a fa­vor­able emerg­ing pro­file of ef­fi­ca­cy and tol­er­a­bil­i­ty due to the com­pet­i­tive en­vi­ron­ment for HER2-tar­get­ed ther­a­pies,” Mer­sana chief Pro­topa­pas said in a state­ment.

Leerink and Cowen an­a­lysts sug­gest­ed Mer­sana’s de­ci­sion was per­ti­nent, con­sid­er­ing the com­pet­i­tive land­scape for HER2-tar­get­ing ther­a­pies. Sev­er­al such ther­a­pies have al­ready been sanc­tioned ap­proval, and oth­ers are in de­vel­op­ment, in­clud­ing Dai­ichi Sankyo’s DS-8201 that car­ries 7-8 pay­loads, not­ed Cowen’s Boris Peak­er.

“Many in­vestors al­ready had very low ex­pec­ta­tions for XMT-1522…es­pe­cial­ly fol­low­ing the brief par­tial clin­i­cal hold placed on XMT-1522 that has con­tributed to the stock trad­ing near his­toric lows. The de­ci­sion to fo­cus re­sources on ad­vanc­ing XMT-1536 could al­so have a pos­i­tive im­pact on the com­pa­ny’s cash run­way,” Leerink an­a­lysts wrote in a note.

The com­pa­ny al­so pro­vid­ed en­cour­ag­ing ini­tial da­ta on XMT-1536 — a NaPi2b- tar­get­ing ADC — from an on­go­ing dose es­ca­la­tion study.

“Ul­ti­mate­ly…it will be im­por­tant for XMT-1536 to demon­strate dura­bil­i­ty of re­spons­es achieved giv­en Roche’s past NaPi2b dis­ap­point­ments,” they added.


Mer­sana con­tact­ed End­points News to as­sert that the Take­da part­ner­ship was ter­mi­nat­ed by mu­tu­al con­sent, echo­ing its press re­lease post­ed on Fri­day. 

Part club, part guide, part land­lord: Arie Bellde­grun is blue­print­ing a string of be­spoke biotech com­plex­es in glob­al boom­towns — start­ing with Boston

The biotech industry is getting a landlord, unlike anything it’s ever known before.

Inspired by his recent experiences scrounging for space in Boston and the Bay Area, master biotech builder, investor, and global dealmaker Arie Belldegrun has organized a new venture to build a new, 250,000 square foot biopharma building in Boston’s Seaport district — home to Vertex and a number of up-and-coming biotech players.

Endpoints News

Basic subscription required

Unlock this story instantly and join 54,900+ biopharma pros reading Endpoints daily — and it's free.

Novotech CRO Ex­pands Chi­na Team as Biotech De­mand for Clin­i­cal Tri­als In­creas­es up to 79%

An increase in demand of up to 79% for clinical trials in China has prompted Novotech the Asia-Pacific CRO to rapidly expand the China team, appointing expert local clinical executives to their Shanghai and Hong Kong offices. The company is planning to expand their team by 30% over the next quarter.

Novotech China has seen considerable demand recently which is borne out by research from GlobalData:
A global migration of clinical research is occurring from high-income countries to low and middle-income countries with emerging economies. Over the period 2017 to 2018, for example, the number of clinical trial sites opened by biotech companies in Asia-Pacific increased by 35% compared to 8% in the rest of the world, with growth as high as 79% in China.
Novotech CEO Dr John Moller said China offers the largest population in the world, rapid economic growth, and an increasing willingness by government to invest in research and development.
Novotech’s 23 years of experience working in the region means we are the ideal CRO partner for USA biotechs wanting to tap the research expertise and opportunities that China offers.
There are over 22,000 active investigators in Greater China, with about 5,000 investigators with experience on at least 3 studies (source GlobalData).

H1 analy­sis: The high-stakes ta­ble in the biotech deals casi­no is pay­ing out some record-set­ting win­nings

For years the big trend among dealmakers at the major players has been centered on ratcheting down upfront payments in favor of bigger milestones. Better known as biobucks for some. But with the top 15 companies competing for the kind of “transformative” pacts that can whip up some excitement on Wall Street, with some big biotechs like Regeneron now weighing in as well, cash is king at the high stakes table.

We asked Chris Dokomajilar, the head of DealForma, to crunch the numbers for us, looking over the top 20 deals for the past decade and breaking it all down into the top alliances already created in 2019. Gilead has clearly tipped the scales in terms of the coin of the bio-realm, with its record-setting $5 billion upfront to tie up to Galapagos’ entire pipeline.

Dokomajilar notes:

We’re going to need a ‘three comma club’ for the deals with over $1 billion in total upfront cash and equity. The $100 million-plus club is getting crowded at 164 deals in the last decade with new deals being added towards the top of the chart. 2019 already has 14 deals with at least $100 million in upfront cash and equity for a total year-to-date of over $9 billion. That beats last year’s $8 billion and sets a record.

Add upfronts and equity payments and you get $11.5 billion for the year, just shy of last year’s record-setting $11.8 billion.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

UP­DAT­ED: With loom­ing ‘apoc­a­lypse of drug re­sis­tance,’ Mer­ck’s com­bi­na­tion an­tibi­ot­ic scores FDA ap­proval on two fronts

Merck — one of the last large biopharmaceuticals companies in the beleaguered field of antibiotic drug development — on Wednesday said the FDA had sanctioned the approval of its combination antibacterial for the treatment of complicated urinary tract and intra-abdominal infections.

To curb the rise of drug-resistant bacteria and maintain the efficacy of the therapy, Recarbrio (and other antibacterials) — the drug must be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible gram-negative bacteria, Merck $MRK said.

Endpoints News

Basic subscription required

Unlock this story instantly and join 54,900+ biopharma pros reading Endpoints daily — and it's free.

John McHutchison in 2012. Getty Images

The $1.1M good­bye: Gilead CSO John McHutchi­son is out as Daniel O’Day shakes up the se­nior team

Just a little more than a year after John McHutchison grabbed a promotion to become CSO at Gilead in the wake of Norbert Bischofberger’s exit, he’s out amid a shakeup of the senior team that is also triggering the departure of two other top execs.

Gilead stated that McHutchison “has decided to step down” from the job as of August 2nd. And their SEC filing notes that he’ll be getting a $1.1 million check to settle up on his contract.

Endpoints News

Basic subscription required

Unlock this story instantly and join 54,900+ biopharma pros reading Endpoints daily — and it's free.

Thomas Gajewski, David Steinberg. (CRI, Pyxis)

Bay­er, Long­wood back star re­searcher's deep dive in­to the tu­mor mi­croen­vi­ron­ment for new I/O tar­gets

From PD-1 targeting to the RAS pathway to the STING complex, Thomas Gajewski has spent the past two decades of his career decoding the various ways the immune system can be unleashed to defend against cancer. So when the University of Chicago professor comes around to putting all his findings into a new platform for finding new targets, VCs and pharma groups alike pay attention.

“He’s been studying T cells for 20 years, plus he’s one of the world’s leaders if not the world leader in the space,” David Steinberg, partner at Longwood Fund, said. “Furthermore, let me add he did a lot of the foundational research and also some of the seminal clinical trials in the existing set of I/O agents. He understands the space really well, he understands the current strengths, and I think he understood really well what was missing, so he knew where to look.”

Kamala Harris speaking yesterday at the Des Moines Register Iowa Presidential Candidate Forum [via Getty]

Who’s the tough­est on drug prices? A game of po­lit­i­cal one-up­man­ship is dri­ving the pol­i­cy de­bate in Wash­ing­ton

Earlier this week we got a look at Senator Kamala Harris’ position on drug prices. She’s proposing that HHS take an average price from single-payer systems like the UK, Germany and Canada — which leverage market access for lower prices — and use that to set the US price. Anything drug companies collect above that would be taxed at a rate of 100%.

And the rhetoric is scathing:
While families struggle to make it to the end of the month, pharmaceutical companies are turning record profits. They’re spending nearly as much on advertising as R&D. They’re manipulating their market power to hike prices on lifesaving generic drugs. They’re making twice the profit of the average industry in America and still increased drug prices by 10.5% over the past six months alone. Meanwhile, they are charging dramatically higher prices to American consumers.
That’s an escalation on Joe Biden’s plan, which includes drug importation from those cheaper markets as well as allowing Medicare to negotiate prices — something that virtually all Dems agree on now.

SJ Lee [File photo]

Go­ing in­side cells, Sung Joo Lee has sketched some big goals for his small — but glob­al — team of drug hunters

For a small biotech based in South Korea with a research arm in Cambridge, MA, Orum Therapeutics has sketched out some big goals aimed at developing antibodies for intracellular targets. And now they have a new $30 million round to push the work forward, aiming at a slate of currently undruggable quests.

Orum has been working on a platform tech out of Ajou University that relies on endocytosis to smuggle antibodies and their cargo inside a cell. They’ve published work in Nature that illustrates its preclinical potential in RAS mutations, and KRAS is on their list of targets. 

Endpoints News

Basic subscription required

Unlock this story instantly and join 54,900+ biopharma pros reading Endpoints daily — and it's free.

Astel­las buys in­to Fre­quen­cy's re­gen­er­a­tive med strat­e­gy with a $625M al­liance on hear­ing loss

The executive team at Frequency Therapeutics never oversold the results of their maiden Phase I/II study for a new drug to rectify hearing loss. It was, they said back in April, primarily about safety and tolerability, where their drug FX-322 performed as they had hoped. 

That early glimpse of efficacy everyone searches for in their first try on humans? 

(I)mprovements in hearing function, including audiometry and word scores, were observed in multiple FX-322 treated patients.

We don’t know exactly what that means. But whatever the details, Astellas found enough in the data to jump in with a sizable collaboration deal.

Endpoints News

Basic subscription required

Unlock this story instantly and join 54,900+ biopharma pros reading Endpoints daily — and it's free.